368 related articles for article (PubMed ID: 29164658)
1. Successful treatment of Raynaud's phenomenon and digital ulcers in systemic sclerosis patients with botulinum toxin B injection: Assessment of peripheral vascular disorder by angiography and dermoscopic image of nail fold capillary.
Motegi SI; Sekiguchi A; Saito S; Ishibuchi H; Kishi C; Yasuda M; Ishikawa O
J Dermatol; 2018 Mar; 45(3):349-352. PubMed ID: 29164658
[TBL] [Abstract][Full Text] [Related]
2. Efficacy of Botulinum Toxin B Injection for Raynaud's Phenomenon and Digital Ulcers in Patients with Systemic Sclerosis.
Motegi SI; Uehara A; Yamada K; Sekiguchi A; Fujiwara C; Toki S; Date Y; Nakamura T; Ishikawa O
Acta Derm Venereol; 2017 Jul; 97(7):843-850. PubMed ID: 28358168
[TBL] [Abstract][Full Text] [Related]
3. Beneficial effect of botulinum toxin A on Raynaud's phenomenon in Japanese patients with systemic sclerosis: A prospective, case series study.
Motegi S; Yamada K; Toki S; Uchiyama A; Kubota Y; Nakamura T; Ishikawa O
J Dermatol; 2016 Jan; 43(1):56-62. PubMed ID: 26173902
[TBL] [Abstract][Full Text] [Related]
4. [Botulinum toxin type A contribution in the treatment of Raynaud's phenomenon due to systemic sclerosis].
Serri J; Legré R; Veit V; Guardia C; Gay AM
Ann Chir Plast Esthet; 2013 Dec; 58(6):658-62. PubMed ID: 22204894
[TBL] [Abstract][Full Text] [Related]
5. A 4-week comparison of capillaroscopy changes, healing effect, and cost-effectiveness of botulinum toxin-A vs prostaglandin analog infusion in refractory digital ulcers in systemic sclerosis.
Shenavandeh S; Sepaskhah M; Dehghani S; Nazarinia M
Clin Rheumatol; 2022 Jan; 41(1):95-104. PubMed ID: 34471968
[TBL] [Abstract][Full Text] [Related]
6. Statins: potentially useful in therapy of systemic sclerosis-related Raynaud's phenomenon and digital ulcers.
Abou-Raya A; Abou-Raya S; Helmii M
J Rheumatol; 2008 Sep; 35(9):1801-8. PubMed ID: 18709692
[TBL] [Abstract][Full Text] [Related]
7. Clinical and image improvement of Raynaud's phenomenon after botulinum toxin type A treatment.
Zhao H; Lian Y
Australas J Dermatol; 2015 Aug; 56(3):202-5. PubMed ID: 25817568
[TBL] [Abstract][Full Text] [Related]
8. The efficacy of botulinum toxin A in the treatment of Raynaud's phenomenon in systemic sclerosis: A randomized self-controlled trial.
Du W; Zhou M; Zhang C; Sun Q
Dermatol Ther; 2022 Jul; 35(7):e15529. PubMed ID: 35441772
[TBL] [Abstract][Full Text] [Related]
9. The novel use of botulinum toxin A for the treatment of Raynaud's phenomenon in the toes.
Dhaliwal K; Griffin M; Denton CP; Butler PEM
BMJ Case Rep; 2018 Mar; 2018():. PubMed ID: 29525756
[TBL] [Abstract][Full Text] [Related]
10. Practical suggestions on intravenous iloprost in Raynaud's phenomenon and digital ulcer secondary to systemic sclerosis: Systematic literature review and expert consensus.
Ingegnoli F; Schioppo T; Allanore Y; Caporali R; Colaci M; Distler O; Furst DE; Hunzelmann N; Iannone F; Khanna D; Matucci-Cerinic M
Semin Arthritis Rheum; 2019 Feb; 48(4):686-693. PubMed ID: 29706243
[TBL] [Abstract][Full Text] [Related]
11. Vascular biomarkers and digital ulcerations in systemic sclerosis: results from a randomized controlled trial of oral treprostinil (DISTOL-1).
Mecoli CA; Perin J; Van Eyk JE; Zhu J; Fu Q; Allmon AG; Rao Y; Zeger S; Wigley FM; Hummers LK; Shah AA
Clin Rheumatol; 2020 Apr; 39(4):1199-1205. PubMed ID: 31858338
[TBL] [Abstract][Full Text] [Related]
12. Prospective, open-label, uncontrolled pilot study to study safety and efficacy of sildenafil in systemic sclerosis-related pulmonary artery hypertension and cutaneous vascular complications.
Kumar U; Sankalp G; Sreenivas V; Kaur S; Misra D
Rheumatol Int; 2013 Apr; 33(4):1047-52. PubMed ID: 22833239
[TBL] [Abstract][Full Text] [Related]
13. Botulinum toxin type A: a treatment option for digital ischemia in patients with Raynaud's phenomenon.
Fregene A; Ditmars D; Siddiqui A
J Hand Surg Am; 2009 Mar; 34(3):446-52. PubMed ID: 19258141
[TBL] [Abstract][Full Text] [Related]
14. Botulinum toxin in the management of primary and secondary Raynaud's phenomenon.
Ennis D; Ahmad Z; Anderson MA; Johnson SR
Best Pract Res Clin Rheumatol; 2021 Sep; 35(3):101684. PubMed ID: 33965340
[TBL] [Abstract][Full Text] [Related]
15. Targeted high concentration botulinum toxin A injections in patients with Raynaud's phenomenon: a retrospective single-centre experience.
Nagarajan M; McArthur P
Rheumatol Int; 2021 May; 41(5):943-949. PubMed ID: 32447423
[TBL] [Abstract][Full Text] [Related]
16. Digital ulcers and cutaneous subsets of systemic sclerosis: Clinical, immunological, nailfold capillaroscopy, and survival differences in the Spanish RESCLE Registry.
Tolosa-Vilella C; Morera-Morales ML; Simeón-Aznar CP; Marí-Alfonso B; Colunga-Arguelles D; Callejas Rubio JL; Rubio-Rivas M; Freire-Dapena M; Guillén-Del Castillo A; Iniesta-Arandia N; Castillo-Palma MJ; Egurbide-Arberas M; Trapiellla-Martínez L; Vargas-Hitos JA; Todolí-Parra JA; Rodriguez-Carballeira M; Marin-Ballvé A; Pla-Salas X; Rios-Blanco JJ; Fonollosa-Pla V;
Semin Arthritis Rheum; 2016 Oct; 46(2):200-208. PubMed ID: 27312381
[TBL] [Abstract][Full Text] [Related]
17. Management of Raynaud's phenomenon and digital ischemia.
Herrick AL
Curr Rheumatol Rep; 2013 Jan; 15(1):303. PubMed ID: 23292819
[TBL] [Abstract][Full Text] [Related]
18. Intravenous iloprost treatment of Raynaud's phenomenon and ischemic ulcers secondary to systemic sclerosis.
Wigley FM; Seibold JR; Wise RA; McCloskey DA; Dole WP
J Rheumatol; 1992 Sep; 19(9):1407-14. PubMed ID: 1279170
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of botulinum toxin type A injection for Raynaud's phenomenon and digital ulcers in patients with systemic sclerosis.
Jokar MH; Baghbani B; Geraylow KR; Shariati J; Mehrad-Majd H; Mirfeizi Z; Hashemzadeh K
Reumatologia; 2022; 60(6):392-398. PubMed ID: 36683833
[TBL] [Abstract][Full Text] [Related]
20. Effect of clonazepam on Raynaud's phenomenon and fingertip ulcers in scleroderma.
Colakoğlu M; Cobankara V; Akpolat T
Ann Pharmacother; 2007 Sep; 41(9):1544-7. PubMed ID: 17666574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
